Skip to main content

Advertisement

Table 3 Predictors of switch to BOT: Univariate and multivariate (pooled) HRs and corresponding lower and upper bounds of the 95 % CIs

From: Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry

  Endpoint
BOT OAD-End
(N = 6,705) (N = 10,547)
Univariate   
 Age 1.000 (0.998,1.002) 1.002 (1.001,1.004)
 BMI 1.016 (1.012,1.020) 1.006 (1.004,1.010)
 Diabetes duration 1.044 (1.041,1.047) 1.003 (0.999,1.007)
 HbA1c 1.264 (1.245,1.284) 1.003 (0.984,1.022)
 FPG 1.127 (1.109,1.046) 1.011 (0.999,1.023)
 Gender 0.934 (0.891,0.981) 1.001 (0.963,1.040)
 Microvascular diseasesa 1.226 (1.168,1.287) 0.974 (0.936,1.014)
 Macrovascular diseasesa 1.115 (1.056,1.178) 1.131 (1.083,1.182)
 Hypoglycaemiaa 2.567 (1.850,3.563) 1.007 (0.634,1.599)
 No. OADs at baseline 2 vs. 1 1.288 (1.206,1.376) 0.679 (0.636,0.725)
 No. OADs at baseline 3 vs. 1 1.295 (1.054,1.592) 0.605 (0.483,0.758)
 Concomitant Medication yes vs. no 1.144 (1.090,1.200) 0.834 (0.802,0.866)
Multivariate   
 Age 0.993 (0.991,0.996) 1.003 (1.001,1.005)
 BMI 1.012 (1.007,1.017) 1.009 (1.005,1.012)
 Diabetes duration 1.046 (1.043,1.049) 1.003 (0.999,1.007)
 HbA1c 1.227 (1.197,1.257) 0.999 (0.970,1.029)
 FPG 1.022 (0.999,1.046) 1.014 (0.997,1.033)
 Gender 0.950 (0.903,0.998) 0.995 (0.956,1.035)
 Microvascular diseasesa 1.141 (1.082,1.203) 0.947 (0.908,0.988)
 Macrovascular diseasesa 1.065 (1.004,1.130) 1.152 (1.100,1.208)
 Hypoglycaemiaa 1.708 (1.208,2.415) 0.956 (0.601,1.520)
 No. OADs at baseline 2 vs. 1 1.121 (1.047,1.199) 0.680 (0.636,0.727)
 No. OADs at baseline 3 vs. 1 0.981 (0.796,1.210) 0.604 (0.482,0.758)
 Concomitant Medication yes vs. no 1.094 (1.042,1.149) 0.824 (0.793,0.857)
  1. Legend: BOT basal supported oral therapy, BMI body mass index, HbA1c glycated haemoglobin, FPG fasting plasma glucose, OAD oral antidiabetic drug, HR hazard ratio. Multivariate adjustment includes all factors given in the table
  2. aPatient and/or physician reported